Back to search results

Neurovascular Regulation During Exercise in Chronic Kidney Disease

This study is looking at how exercise capacity is affected in people with chronic kidney disease (CKD). Researchers want to understand why people with CKD often have trouble exercising and how to improve this. You might be eligible if you are between 40 and 75 years old, have CKD (stages III and IV), have received a kidney transplant, or do not have kidney disease but will serve as a control. You should also be someone who doesn't exercise regularly. Participants will either take sodium bicarbonate pills or a placebo (an inactive pill that looks like the real medicine) twice daily, and also participate in a 12-week exercise training program on stationary bikes. The main goal is to see if these interventions can improve your exercise capacity.

Study design
This is an interventional study with 156 planned participants. It compares the effects of sodium bicarbonate and exercise training to a placebo.
What's involved
You would take pills twice daily and have your serum bicarbonate levels checked regularly. You would also attend three exercise sessions per week for 12 weeks.
Compensation
Not stated in the trial record.
Follow-up
Your exercise capacity will be measured at the beginning of the study and again at Week 12.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05928936

Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD

Recruiting
PHASE2Ages 40–75InterventionalBasic science
Emory University
~156 participants
Updated 2025-10-21 on ClinicalTrials.gov
What's tested:Sodium BicarbonateExercise TrainingPlacebo

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Exercise Capacity
Measured over Baseline, Week 12

Conditions

Chronic Kidney Disease

Explore related trials

Chronic Kidney Disease

NCT05928936

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Atlanta VA Medical Center

    Decatur, Georgiano site contact published

    Recruiting

  • Emory Clinic

    Atlanta, Georgiano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Jeanie Park, MD · PRINCIPAL_INVESTIGATOR · Emory University

Who to contact

Dana DaCosta
[email protected]
404-727-7762
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

patients with CKD (Stages III and IV), kidney transplant recipients with varying degrees of kidney function, or persons without kidney disease as matched study controls
sedentary and do not regularly exercise (defined as exercising \< 20 minutes twice per week)
CKD patients must have stable renal function (no greater than a decline of estimated glomerular filtration (eGFR) of 1 cc/min/1.73 m2 per month over the prior 6 months) and baseline serum bicarbonate 22-24 mmol/L
comorbid hypertension

Exclusion

severe CKD (eGFR\<15 cc/min)
metabolic alkalosis
current treatment with bicarbonate
ongoing drug or alcohol abuse
diabetic neuropathy, autonomic dysfunction
any serious disease that might influence survival
anemia with hemoglobin \<10 g/dL
clinical evidence of heart failure
volume overload or ejection fraction below 45%
symptomatic heart disease by EKG, stress test, and/or history
treatment with central α-agonists (clonidine)
myocardial infarction or cerebrovascular accident within the past six months
uncontrolled hypertension (BP\>170/100 mm Hg)
low BP\<100/50 mm Hg
surgery within the past 3 months
pregnancy or plans to become pregnant
inability to exercise on a stationary bicycle
contraindication to temporary withdrawal of α- and β-blockers
peripheral arterial disease
class 3 obesity (BMI\>40)
hypo- or hyperkalemia (K\<3.5meq/L, K\>5.0 meq/L)
current use of immunosuppressive medications (including but not limited to steroids, cyclophosphamide, calcineurin inhibitors, mycophenolate, biologics, methotrexate, etc)
arteriovenous (AV) fistula/graft
any contraindication to MR scanning including cardiac pacemaker, cochlear implants, neurostimulators, implanted devices with metal, any metal in the body that could pose a hazard during scanning, history of claustrophobia

What this trial measures

  • Change in Exercise CapacityBaseline, Week 12

    Exercise capacity measured as VO2 peak during a maximal treadmill exercise test. Higher VO2 max indicates increased oxygen consumption and improved fitness.